Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed the day trading at $17.92 down -0.44% from the previous closing price of $18.0. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 1.29 million shares were traded. SPRY stock price reached its highest trading level at $18.1582 during the session, while it also had its lowest trading level at $17.695.
Ratios:
For a better understanding of SPRY, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.74 and its Current Ratio is at 11.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $30.
On February 10, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 01 ’25 when Karas Eric sold 15,000 shares for $16.99 per share. The transaction valued at 254,860 led to the insider holds 10,315 shares of the business.
Flynn James E sold 740,149 shares of SPRY for $13,663,151 on Jun 27 ’25. The 10% Owner now owns 4,887,254 shares after completing the transaction at $18.46 per share. On Jul 01 ’25, another insider, ERIC KARAS, who serves as the Officer of the company, bought 15,000 shares for $16.99 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1759987712 and an Enterprise Value of 1553715968. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.12 while its Price-to-Book (P/B) ratio in mrq is 7.68. Its current Enterprise Value per Revenue stands at 15.998 whereas that against EBITDA is -58.148.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.90, which has changed by 0.63205826 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $8.91. The 50-Day Moving Average of the stock is 13.28%, while the 200-Day Moving Average is calculated to be 29.49%.
Shares Statistics:
Over the past 3-months, SPRY traded about 1.37M shares per day on average, while over the past 10 days, SPRY traded about 1095710 shares per day. A total of 98.13M shares are outstanding, with a floating share count of 55.56M. Insiders hold about 43.43% of the company’s shares, while institutions hold 53.93% stake in the company. Shares short for SPRY as of 1751241600 were 15789752 with a Short Ratio of 11.53, compared to 1748563200 on 17135687. Therefore, it implies a Short% of Shares Outstanding of 15789752 and a Short% of Float of 26.299998000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of ARS Pharmaceuticals Inc (SPRY) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.32 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.44 and -$1.62 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$0.69, with 4.0 analysts recommending between -$0.45 and -$1.07.
Revenue Estimates
6 analysts predict $13.77M in revenue for the current quarter. It ranges from a high estimate of $17.5M to a low estimate of $10.5M. As of the current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $500kFor the next quarter, 6 analysts are estimating revenue of $28.73M. There is a high estimate of $39.5M for the next quarter, whereas the lowest estimate is $13M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $94.28M, while the lowest revenue estimate was $55.6M, resulting in an average revenue estimate of $79.7M. In the same quarter a year ago, actual revenue was $89.15MBased on 6 analysts’ estimates, the company’s revenue will be $206.01M in the next fiscal year. The high estimate is $248.41M and the low estimate is $117.6M.
